Condition
Hereditary Angioedema (HAE) clinical trials and research
As of November 12, 2026, Find a Trial lists 5 Hereditary Angioedema (HAE) clinical trials that are recruiting, at sites in 22 countries (most in United States (3), Australia (2), Poland (2)). By phase: Phase 3 (2), Phase 1/2 (1). Every study is explained in plain English. Data from ClinicalTrials.gov and NIH RePORTER, updated November 12, 2026.
- 5Clinical trials
- 22Countries
Newest Hereditary Angioedema (HAE) clinical trials
| Study | Phase | Where | Status | Registered |
|---|---|---|---|---|
| Takhzyro use in teenagers and adults with hereditary angioedema in South Korea | — | Suwon, Gyeonggi-do and 2 other locations | Recruiting | Mar 3, 2026 |
| Long-term treatment with ADX-324 for people with hereditary angioedema | Phase 3 | Litchfield Park, Arizona and 47 other locations | Recruiting | Feb 23, 2026 |
| Donidalorsen for children with hereditary angioedema | Phase 3 | Santa Monica, California and 17 other locations | Recruiting | Dec 23, 2025 |
| C1-Inhibitor Function Test to Diagnose HAE in Algeria | — | Algiers | Recruiting | Dec 19, 2025 |
| Oral deucrictibant to prevent and treat hereditary angioedema attacks | Phase 1/2 | Wheaton, Maryland | Recruiting | Jul 2, 2025 |
All recruiting trials (5)
-
Takhzyro use in teenagers and adults with hereditary angioedema in South Korea
This study looks at how safe and useful Takhzyro is when used in real-world care for teenagers and adults with hereditary angioedema in South Korea.
-
Long-term treatment with ADX-324 for people with hereditary angioedema
This extension will try additional doses of ADX-324 (onvuzosiran) to see if continuing the drug is safe and helps people with Type I or II hereditary angioedema who finished the earlier Phase 3 trial.
-
Donidalorsen for children with hereditary angioedema
This trial tests if donidalorsen is safe and how it is processed in the body for children aged 2 to under 12 with hereditary angioedema types I or II.
-
C1-Inhibitor Function Test to Diagnose HAE in Algeria
A test that measures C1-inhibitor function is being tried to see if it can accurately diagnose hereditary angioedema in patients in Algeria.
-
Oral deucrictibant to prevent and treat hereditary angioedema attacks
This trial tests whether daily oral deucrictibant XR can prevent angioedema attacks and whether deucrictibant capsules can quickly relieve acute attacks in adults with bradykinin-mediated hereditary angioedema.
Related topics
Quick answers
How many Hereditary Angioedema (HAE) clinical trials are recruiting right now?
5, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.
Where are these trials running?
In 22 countries. The most sites are in United States (3 trials), Australia (2 trials), Poland (2 trials), Spain (2 trials), Algeria (1 trial). Each study page lists its sites and which ones are recruiting.
What phases are they in?
Phase 3: 2, Phase 1/2: 1. Trials with no phase listed are usually device, behavioural or observational studies.
How do I join one?
Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.
Find the studies that fit you
A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.